The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Glucose Catabolism in Cancer Cells
Open accessAbstract
The p53 tumor suppressor is found to be mutated and abundant in a wide variety of tumors. Within tumors showing rapid growth, the Type II isoform of hexokinase is also highly expressed to facilitate high rates of glucose catabolism, which in turn promote their rapid proliferation. We previously reported isolation of the proximal promoter of the Type II hexokinase gene from the highly glycolytic hepatoma AS-30D (Mathupala, S. P., Rempel, A., and Pedersen, P. L. (1995) J. Biol. Chem. 270, 16918-16925). Here, we show that a p53 protein, exhibiting two point mutations in its cDNA, is abundantly expressed in the AS-30D hepatoma. Co-expression studies showed that p53 overexpression significantly and reproducibly activated the Type II hexokinase promoter. Two functional p53 motifs were identified within this promoter by footprint and gel retardation analyses. Presence of functional p53 response elements on the Type II hexokinase promoter and the positive regulatory effect on the promoter by the mutant p53 indicates that in rapidly growing liver tumors, and perhaps in many other tumors as well, this highly abundant p53 protein plays a role in maintaining a high glycolytic rate. This is the first report of a possible link between loss of cell cycle control in rapidly growing cancer cells and their high glycolytic phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Wild-type p53 activates transcription in vitro
Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., & Prives, C. (1992) · Nature · doi:10.1038/358083a0 · Cited by 579
Cited by
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Glycolysis inhibition for anticancer treatment
Pelicano, H., Martin, D. S., Xu, R.-H., & Huang, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209597 · Cited by 1,516
Oncogenic alterations of metabolism
Dang, C. V., & Semenza, G. L. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(98)01344-9 · Cited by 1,106
P53 in survival, death and metabolic health: a lifeguard with a licence to kill.
Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4007 · Cited by 1,080
Vousden, K. H., & Ryan, K. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2715 · Cited by 959
Mathupala, S. P., Ko, Y. H., & Pedersen, P. L. (2006) · Oncogene · doi:10.1038/sj.onc.1209603 · Cited by 765
Self-citationDichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
Michelakis, E. D., Webster, L., & Mackey, J. R. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604554 · Cited by 656
Cancer metabolism: facts, fantasy, and fiction
Zu, X. L., & Guppy, M. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.136 · Cited by 618
Bos, R., van der Hoeven, J. J. M., van der Wall, E., van der Groep, P., van Diest, P. J., Comans, E. F. I., Joshi, U., Semenza, G. L., Hoekstra, O. S., Lammertsma, A. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.379 · Cited by 591
Mathupala, S. P., Ko, Y. H., & Pedersen, P. L. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.11.006 · Cited by 574
Self-citationMetabolic Regulation by p53 Family Members
Berkers, C. R., Maddocks, O. D. K., Cheung, E. C., Mor, I., & Vousden, K. H. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.06.019 · Cited by 446
Pedersen, P. L. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-007-9094-x · Cited by 425
Self-citationLacroix, M., Riscal, R., Arena, G., Linares, L. K., & Le Cam, L. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.10.002 · Cited by 373
Glucose Catabolism in Cancer Cells
Mathupala, S. P., Rempel, A., & Pedersen, P. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108181200 · Cited by 373
Self-citationPedersen, P. L., Mathupala, S., Rempel, A., Geschwind, J. F., & Ko, Y. H. (2002) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(02)00248-7 · Cited by 356
Self-citationMetabolic Reprogramming in Glioma
Strickland, M., & Stoll, E. A. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00043 · Cited by 345
Gain-of-function mutant p53 in cancer progression and therapy
Zhang, C., Liu, J., Xu, D., Zhang, T., Hu, W., & Feng, Z. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa040 · Cited by 334
Chen, J.-Q., & Russo, J. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.06.004 · Cited by 327
Tumor suppressor p53 and metabolism
Liu, J., Zhang, C., Hu, W., & Feng, Z. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy070 · Cited by 300
Wang, L., Xiong, H., Wu, F., Zhang, Y., Wang, J., Zhao, L., Guo, X., Chang, L.-J., Zhang, Y., You, M. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.053 · Cited by 288
Mitochondria and Cancer: Warburg Addressed
WALLACE, D. C. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.035 · Cited by 285
Cancer metabolism: The Warburg effect today
Ferreira, L. M. R. (2010) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2010.08.006 · Cited by 281
The Role of p53 in Metabolic Regulation
Puzio-Kuter, A. M. (2011) · Genes & Cancer · doi:10.1177/1947601911409738 · Cited by 273
Cuproptosis: p53-regulated metabolic cell death?
Xiong, C., Ling, H., Hao, Q., & Zhou, X. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01125-0 · Cited by 263
Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology
Sutendra, G., & Michelakis, E. D. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00038 · Cited by 262
The complexity of p53-mediated metabolic regulation in tumor suppression
Liu, Y., & Gu, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.010 · Cited by 261
Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies
Zhang, Y., Li, Q., Huang, Z., Li, B., Nice, E. C., Huang, C., Wei, L., & Zou, B. (2022) · Cancers · doi:10.3390/cancers14194568 · Cited by 144
Regulation of Metabolic Activity by p53
Flöter, J., Kaymak, I., & Schulze, A. (2017) · Metabolites · doi:10.3390/metabo7020021 · Cited by 81
The unfolded protein response and cancer: A brighter future unfolding?
Scriven, P., Brown, N. J., Pockley, A. G., & Wyld, L. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0150-5 · Cited by 67
CerS6 Is a Novel Transcriptional Target of p53 Protein Activated by Non-genotoxic Stress
Fekry, B., Jeffries, K. A., Esmaeilniakooshkghazi, A., Ogretmen, B., Krupenko, S. A., & Krupenko, N. I. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.716902 · Cited by 59
Metadata
- Authors
- Mathupala, S. P., Heese, C., & Pedersen, P. L.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1997-09
- Volume
- 272
- Issue
- 36
- Pages
- 22776-22780
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1981079102
- Cited by
- 231
- References
- 3
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.